Alphabet-backed health technology company Verily has secured a $300 million investment round. Series X Capital led the funding. Alphabet, UCHealth, and the University of Colorado Anschutz also participated. Together, these investors will help Verily accelerate its AI-native precision health platform. This marks a major milestone in the company’s decade-long journey from a Google X moonshot to a standalone health tech leader.
What the Funding Round Covers
The new capital will fuel three core priorities. First, Verily plans to scale its AI platform to unify fragmented healthcare data. Second, it will deploy actionable intelligence directly into clinical research and care workflows. Third, it will deepen strategic partnerships across the health technology ecosystem.
Notably, Alphabet will now hold a significant minority stake in the company. Furthermore, Alphabet no longer maintains a controlling interest. This transition signals Verily’s maturity as an independent business.
Stephen Gillett, Chairman and CEO of Verily, framed the moment clearly. “Today is an important step in our mission to bring the promise of precision health to everyone,” he said. He added that the goal is to combine clinical rigor with AI to build healthcare that is “as precise as it is personal.”
Verily’s Vision for Precision Health
What Is Precision Health?
Precision health uses data, AI, and scientific research to deliver care that is tailored to each individual. Rather than treating populations broadly, it focuses on personalized, predictive, and preventative solutions. Verily sits at the intersection of technology, data science, and healthcare to make this vision scalable.
How Verily’s Platform Works
Verily’s AI-native Pre Platform transforms multimodal health data into insights and actionable models. Clinicians and researchers can then deploy these models directly into their workflows. As a result, care becomes faster, more accurate, and better aligned with individual patient needs.
New Corporate Structure and Identity
Along with the funding, Verily completed a significant legal transition. The company converted its structure from an LLC to a corporation. Its official new name is Verily Health Inc.
This change reflects the company’s broader ambitions. Moreover, it positions Verily for stronger institutional partnerships and future investment opportunities. The restructuring also aligns the company with standard governance expectations for enterprise health technology firms.
Key Partnerships Driving Growth
Samsung Galaxy Watch Integration
Verily recently announced a collaboration with Samsung’s Galaxy Watch. Through this partnership, life sciences customers can accelerate clinical research. Specifically, the integration supports biomarker development on the Pre Platform, turning consumer wearables into powerful research tools.
Salesforce Agentforce Partnership
Additionally, Verily integrated its Pre Platform with Salesforce’s Agentforce Health. This partnership enables enterprise precision health solutions at scale. Consequently, healthcare organizations can harmonize patient data and act on AI-driven insights within existing Salesforce workflows.
UCHealth and University of Colorado Anschutz
Verily also expanded its collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience. These partners use the Pre Platform for AI-powered research and care transformation. Richard Zane, MD, UCHealth’s Chief Medical and Innovation Officer, described the collaboration as “a generational opportunity for medicine.” He stressed that the partnership will “save lives” by unlocking the long-promised potential of personalized care.
What Investors Are Saying
Series X Capital’s Perspective
Gideon Yu, Founder and Managing Partner of Series X Capital, expressed strong confidence in Verily. “Series X Capital was established to scale moonshot technologies into consequential, world-changing companies,” he said. He called this round a milestone, citing Verily’s growing commercial momentum as a precision health leader.
Alphabet’s Continued Commitment
Ruth Porat, President and Chief Investment Officer of Alphabet and Google, also weighed in. She applauded Verily’s work in tackling longstanding healthcare challenges. “Bringing in new investors, alongside Alphabet’s ongoing involvement, enables Verily to further scale the business,” she noted. The goal, she added, is to improve patient outcomes and lower the cost of healthcare delivery.
Why This Matters for Healthcare
A Shift Toward AI-Native Care
The health technology industry is moving fast. Traditional care models struggle to keep up with growing data volumes and complex patient needs. Therefore, AI-native platforms like Verily’s are increasingly essential. They bridge the gap between raw clinical data and meaningful, timely action.
Verily’s Decade of Progress
Verily originally graduated from Google X ten years ago. It started as one of Alphabet’s earliest “Other Bets,” focused on breakthrough science and health innovation. Today, it has evolved into a full-stack precision health platform company. Its transition to Verily Health Inc. reflects both its growth and its independence.
The Road Ahead
With $300 million in fresh capital and a growing roster of partnerships, Verily is well-positioned for its next phase. The company will continue building tools that make healthcare more personalized, predictive, and precise. Ultimately, the goal is straightforward: better outcomes for every patient, at every stage of care.
